PROGESTERONE RECEPTOR ANTAGONISTS AND USES THEREOF
申请人:Rafestin-Oblin Marie-Edith
公开号:US20130203718A1
公开(公告)日:2013-08-08
The present invention relates to a compound of formula (I): for its use as progesterone receptor antagonist, in particular for its use for the prevention and/or the treatment of cancer or uterine pathologies.
NON-BIOCONVERTIBLE C3-SUBSTITUTED PREGNENOLONE DERIVATIVES FOR USE IN THE TREATMENT OF SUBSTANCE USE DISORDERS
申请人:Mapreg
公开号:EP3165225A1
公开(公告)日:2017-05-10
The present invention relates to the use of non-bioconvertible C3-substituted pregnenolone derivatives of formula (I), with no significant affinity for hormonal receptors or receptors of the central nervous system, in the treatment of substance use disorders, and in particular of alcohol use disorder.
Non-bioconvertible C3-substituted pregnenolone derivatives for use in the treatment of substance use disorders
申请人:MAPREG
公开号:US11077122B2
公开(公告)日:2021-08-03
The present invention relates to the use of non-bioconvertible C3-substituted pregnenolone derivatives of formula (I), with no significant affinity for hormonal receptors or receptors of the central nervous system, in the treatment of substance use disorders, and in particular of alcohol use disorder.